The global tuberculosis burden remains substantial, with more than 10 million people newly
ill per year. Nevertheless, tuberculosis incidence has slowly declined over the past decade …

Together, SARS-CoV-2 and M. tuberculosis have killed approximately 5.7 million people
worldwide over the past 2 years. The COVID-19 pandemic, and the non-pharmaceutical …

Summary Background The SARS-CoV-2 omicron variant of concern was identified in South
Africa in November, 2021, and was associated with an increase in COVID-19 cases. We …

Omicron lineages BA. 4 and BA. 5 drove a fifth wave of COVID-19 cases in South Africa.
Here, we use the presence/absence of the S-gene target as a proxy for SARS-CoV-2 …

Background WHO has established a Global Clinical Platform for the clinical characterisation
of COVID-19 among hospitalised individuals. We assessed whether people living with HIV …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections may be
underestimated because of limited access to testing. We measured SARS-CoV-2 …

Background We describe demographic features, treatments and clinical outcomes in the
International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID …

Background The impact of the COVID-19 pandemic on tuberculosis control in high-burden
countries has not been adequately assessed. We aimed to estimate the impact of the COVID …

Background There is a paucity of data on COVID-19 vaccines in people living with HIV-1,
who could be at increased risk of severe illness and death from COVID-19. We evaluated …

The global pandemic of coronavirus disease 2019 (COVID-19) has disproportionately
impacted global human health, economy, and security. Because of weaker health-care …